Glucotoxicity of the peritoneal membrane: The case for VEGF

Nephrology Dialysis Transplantation

Volumn 16, Issue 12, 2001, Pages 2299-2302

  De Vriese, An S ^a   Mortier, Siska ^a   Lameire, Norbert H ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Advanced glycation end products; Glucose degradation products; Vascular endothelial growth factor

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINO ACID; DIALYSIS FLUID; GLUCOSE; GLUCOSE DERIVATIVE; GLYCEROL; ICODEXTRIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; DRUG FORMULATION; EDITORIAL; EXPOSURE; GLUCOSE METABOLISM; HUMAN; MEMBRANE; MEMBRANE TRANSPORT; NONHUMAN; PATHOGENICITY; PERITONEAL DIALYSIS; PERITONEUM; PRIORITY JOURNAL; RAT; TOXICITY; ULTRAFILTRATION;

EID: 0035210744     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/16.12.2299     Document Type: Editorial

References (39)

1. Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis
2. Functional longevity of the human peritoneum: How long is continuous peritoneal dialysis possible? Results of a prospective medium long-term study
3. Impact of surface area and permeability on solute clearances
4. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis
5. Submesothelial fibrosis in the peritoneal membrane of patients on peritoneal dialysis correlates with the presence of vasculopathy
6. Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis
7. The peritoneal biopsy registry: A watchdog for peritoneal dialysis
8. Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure
9. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultrafiltration
10. Vascular endothelial growth factor and its receptors
11. Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor
12. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes
13. Spontaneous VEGF production by cultured peritoneal mesothelial cells from patients on peritoneal dialysis
14. Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids
15. Growth factors VEGF and TGF-beta 1 in peritoneal dialysis
16. Vascular endothelial growth factor in peritoneal dialysis: A longitudinal follow-up
17. Diabetes-induced microvascular proliferation and hyperpermeability in the peritoneum: Role of vascular endothelial growth factor
18. Glucose degradation products: Relationship with cell damage
19. Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: Role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis
20. Alterations in nonenzymatic biochemistry in uremia: Origin and significance of 'carbonyl stress' in long-term uremic complications
21. 3-Deoxyglucosone, a promoter of advanced glycation end products in fluids for peritoneal dialysis
22. Induction of 1,2-dicarbonyl compounds, intermediates in the formation of advanced glycation end-products, during heat-sterilization of glucose-based peritoneal dialysis fluids
23. Early and advanced glycosylation end products. Kinetics of formation and clearance in peritoneal dialysis
24. Immuno-histochemical study of human advanced glycosylation end-products (AGE) in chronic renal failure
25. Immuno-histochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD
26. Peritoneal accumulation of AGE and peritoneal membrane permeability
27. Amadori albumin and advanced glycation end-product formation in peritoneal dialysis using icodextrin
28. Advanced glycation end products increase retinal vascular endothelial growth factor expression
29. Small-solute transport across specific peritoneal tissue surfaces in the rat
30. Strategies to reduce glucose exposure in peritoneal dialysis patients
31. Reduced 1, 2-dicarbonyl compounds in bicarbonate/lactate-buffered peritoneal dialysis (PD) fluids and PD fluids based on glucose polymers or amino acids
32. Glycation and advanced glycation end-product formation with icodextrin and dextrose
33. Decreased in vitro formation of AGEs with extraneal solution compared to dextrose-containing peritoneal dialysis solutions
34. Advanced glycosylation end-products in diabetic rats on peritoneal dialysis using various solutions
35. Neoangiogenesis in the peritoneal membrane
36. Peritoneal kinetics and mesothelial markers in CCPD using icodextrin for daytime dwell for two years
37. Comparison of in vitro AGE formation between standard PD fluid and a novel bicarbonate/lactate formulation
38. Effects of bicarbonate/lactate solution on peritoneal advanced glycosylation end-product accumulation
39. A commercially available PD fluid with high pH and low GDP induces different morphological changes of rat peritoneum in intermittent PD